| Published Application/Species/Sample/Dilution | Reference |
|---|
- western blot; mouse; loading ...; fig 1h
- western blot; human; loading ...; fig 1a
| Stivala S, Codilupi T, Brkic S, Baerenwaldt A, Ghosh N, Hao Shen H, et al. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. J Clin Invest. 2019;130:1596-1611 pubmed publisher |
- western blot; mouse; loading ...; fig 5b
| Chorzalska A, Morgan J, Ahsan N, Treaba D, Olszewski A, Petersen M, et al. Bone marrow-specific loss of ABI1 induces myeloproliferative neoplasm with features resembling human myelofibrosis. Blood. 2018;: pubmed publisher |
- western blot; human; fig 4a
| Morgan E, Wasson C, Hanson L, Kealy D, Pentland I, McGuire V, et al. STAT3 activation by E6 is essential for the differentiation-dependent HPV18 life cycle. PLoS Pathog. 2018;14:e1006975 pubmed publisher |
- western blot; mouse; loading ...; fig 5b
| Bagarolli R, Tobar N, Oliveira A, Araújo T, Carvalho B, Rocha G, et al. Probiotics modulate gut microbiota and improve insulin sensitivity in DIO mice. J Nutr Biochem. 2017;50:16-25 pubmed publisher |
- western blot; human; loading ...; fig 4
| Ma Y, Chen L, Xie G, Zhou Y, Yue C, Yuan X, et al. Elevated level of interleukin-35 in colorectal cancer induces conversion of T cells into iTr35 by activating STAT1/STAT3. Oncotarget. 2016;7:73003-73015 pubmed publisher |
| Zhang Y, Hu S, Chen Y, Guo M, Wang S. Hepatocyte growth factor inhibits hypoxia/reoxygenation-induced activation of xanthine oxidase in endothelial cells through the JAK2 signaling pathway. Int J Mol Med. 2016;38:1055-62 pubmed publisher |
- western blot; mouse; fig s5
| Krause C, Popp O, Thirunarayanan N, Dittmar G, Lipp M, Müller G. MicroRNA-34a promotes genomic instability by a broad suppression of genome maintenance mechanisms downstream of the oncogene KSHV-vGPCR. Oncotarget. 2016;7:10414-32 pubmed publisher |
- western blot; human; fig 3
| Wu L, Guo L, Liang Y, Liu X, Jiang L, Wang L. Curcumin suppresses stem-like traits of lung cancer cells via inhibiting the JAK2/STAT3 signaling pathway. Oncol Rep. 2015;34:3311-7 pubmed publisher |
- western blot; human; fig 2d
| Roncero A, López Nieva P, Cobos Fernández M, Villa Morales M, González Sánchez L, López Lorenzo J, et al. Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development. Leukemia. 2016;30:94-103 pubmed publisher |
| Huang S, Lee C, Wang H, Chang Y, Lin C, Chen C, et al. 6-Dehydrogingerdione restrains lipopolysaccharide-induced inflammatory responses in RAW 264.7 macrophages. J Agric Food Chem. 2014;62:9171-9 pubmed publisher |
| Hashwah H, Bertram K, Stirm K, Stelling A, Wu C, Kasser S, et al. The IL-6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B-cell lymphoma. EMBO Mol Med. 2019;11:e10576 pubmed publisher |
| Schulz Heddergott R, Stark N, Edmunds S, Li J, Conradi L, Bohnenberger H, et al. Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion. Cancer Cell. 2018;34:298-314.e7 pubmed publisher |
| Zhang X, Li J, Qin J, Cheng W, Zhu X, Gong F, et al. Oncostatin M receptor β deficiency attenuates atherogenesis by inhibiting JAK2/STAT3 signaling in macrophages. J Lipid Res. 2017;58:895-906 pubmed publisher |
| Bu P, Le Y, Zhang Y, Zhang Y, Cheng X. Berberine-induced Inactivation of Signal Transducer and Activator of Transcription 5 Signaling Promotes Male-specific Expression of a Bile Acid Uptake Transporter. J Biol Chem. 2017;292:4602-4613 pubmed publisher |
| Abubaker K, Luwor R, Escalona R, McNally O, Quinn M, Thompson E, et al. Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden. Front Oncol. 2014;4:75 pubmed publisher |
| Zhang H, Yea K, Xie J, Ruiz D, Wilson I, Lerner R. Selecting agonists from single cells infected with combinatorial antibody libraries. Chem Biol. 2013;20:734-41 pubmed publisher |
| Russell M, Cooper A, Dhayal S, Morgan N. Differential effects of interleukin-13 and interleukin-6 on Jak/STAT signaling and cell viability in pancreatic ?-cells. Islets. 2013;5:95-105 pubmed publisher |
| Weigert O, Lane A, Bird L, Kopp N, Chapuy B, Van Bodegom D, et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med. 2012;209:259-73 pubmed publisher |
| Singh S, Verma R, Pradeep A, Leu K, Mortensen R, Young P, et al. Dynamic ligand modulation of EPO receptor pools, and dysregulation by polycythemia-associated EPOR alleles. PLoS ONE. 2012;7:e29064 pubmed publisher |
| Bhattacharyya S, Zhao Y, Kay T, Muglia L. Glucocorticoids target suppressor of cytokine signaling 1 (SOCS1) and type 1 interferons to regulate Toll-like receptor-induced STAT1 activation. Proc Natl Acad Sci U S A. 2011;108:9554-9 pubmed publisher |
| Metlakunta A, Sahu M, Yasukawa H, Dhillon S, Belsham D, Yoshimura A, et al. Neuronal suppressor of cytokine signaling-3 deficiency enhances hypothalamic leptin-dependent phosphatidylinositol 3-kinase signaling. Am J Physiol Regul Integr Comp Physiol. 2011;300:R1185-93 pubmed publisher |
| Ahluwalia M, Donovan H, Singh N, Butcher L, Erusalimsky J. Anagrelide represses GATA-1 and FOG-1 expression without interfering with thrombopoietin receptor signal transduction. J Thromb Haemost. 2010;8:2252-61 pubmed publisher |
